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Abstract
Background: It is recommended that general practitioners (GPs) offer cessation advice and pharmacological interven-
tions to smokers with acute coronary syndrome (ACS). The study objective was to describe the extent to which this is
done, and to describe outcomes by smoking status.
Design: Patients aged 30þ hospitalised for troponin-positive ACS from 2002 to 2009, discharged home alive, were
identified in the Myocardial Ischaemia National Audit Project registry. Patient data were linked to the General Practice
Research Database, Hospital Episode Statistics, and Office of National Statistics mortality data, enabling a unique per-
spective of longitudinal smoking data. Patients who smoked prior to the hospitalisation had GP interventions and quitting
status established in the 3 months following discharge, and were followed up for major clinical outcomes.
Methods: The outcomes evaluated included death, repeat ACS, stroke, heart failure, and major adverse cardiac events
(MACE).
Results:Of the 4834 patients included, 965 (20%) were smokers at the time of their ACS. After the ACS event, only 225
(24%) received any GP smoking intervention within 3 months, with 82 (9%) receiving advice only, and 143 (15%) receiving
a pharmacological intervention. Patients who quit (320; 33%) were at a decreased risk of mortality (relative risk (RR)
0.49; 95% confidence interval (CI) 0.35–0.69) and MACE (RR 0.61; 0.46–0.80) compared with patients who did not.
Conclusions: Whilst a high proportion of patients with ACS are smokers, there is a low level of GP cessation inter-
vention following hospital discharge. This missed opportunity of patient care is important given the decreased risk of
mortality and MACE found amongst those who quit.
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Introduction
Acute coronary syndrome (ACS) occurs in around
130,000 patients in England and Wales each year.
Smoking is a major risk factor for ACS, whilst quitting
smoking is associated with a 36% reduction in risk of
all-cause mortality and a 32% reduction in non-fatal
myocardial infarction among patients with coronary
heart disease.1 A recent study found that smoking
relapse after ACS is associated with a signiﬁcant
increase in all-cause mortality in these patients and
that an earlier resumption of smoking is associated
with a greater risk of death compared with a later
relapse.2
It is recommended internationally that general prac-
titioners (GPs) oﬀer smoking cessation advice and
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treatment to smokers who have ACS.3 Smoking cessa-
tion advice from GPs, given during routine consult-
ations, encourages patients to stop smoking and
pharmacological interventions may double the eﬀect-
iveness of advice alone.4–6 A Cochrane review states
that, for cardiovascular inpatients, intensive counsel-
ling intervention begun in hospital and continued
with supportive contacts for at least 1 month after dis-
charge is the only non-pharmacological intervention
that delivers an increase in smoking cessation rates.
Less intensive counselling intervention has no inﬂuence
on cessation rates.7
The Myocardial Ischaemia National Audit Project
(MINAP) registry has collected data on patients with
myocardial infarction since 1998 and more recently col-
lects information on the treatment of patients who have
been admitted to hospital with ACS.8 However, no
information on the treatment of these patients once
they have been discharged into primary care is collected.
The General Practice Research Database (GPRD)
collates the computerised medical records of GPs.
GPs play a key role in the UK healthcare system as
they are responsible for primary healthcare and special-
ist referrals. Patients are semi-permanently aﬃliated
with a practice that centralises the medical information
from the GPs, specialist referrals and hospitalisations.
The data recorded in the GPRD include demographic
information, prescription details, clinical events, pre-
ventative care, specialist referrals, hospital admissions
and major outcomes.9 However, in-depth information
on events occurring in secondary care is not compre-
hensively recorded.
GPRD can now be linked individually and anonym-
ously to otherNationalHealth Service (NHS) datasets in
England, including MINAP. When this study was con-
ducted 224GPpractices in Englandwere participating in
the linkage (approximately 45% of all GPRD practices).
The linkage between the secondary care data within
MINAP and the primary care data in the GPRD
allows studies that follow patients throughout their
NHS care to give a more complete picture of the treat-
ment and outcomes of patients in England, such as those
withACS.Of particular interest is the unique perspective
this linkage provides on longitudinal smoking status.
The objective of this study was to utilise the linked
GPRD-MINAP record to describe the extent of smok-
ing cessation advice and pharmaceutical interventions
for smoking cessation provided by GPs following ACS
and to describe patient outcomes stratiﬁed by smoking
status.
Methods
This retrospective observational study utilised linked
data from the MINAP, GPRD, Hospital Episode
Statistics (HES) and Oﬃce of National Statistics
(ONS) mortality datasets. Linkage between participat-
ing GPRD practices and MINAP required both to send
information on patient identiﬁers, including NHS
number, to a trusted third party. The linkage was
done in two passes. The ﬁrst pass matched patients
on NHS number, sex and partial date of birth. The
second pass matched patients on sex, date of birth
and postcode. After matching, the patient identiﬁers
were removed. The study protocol was reviewed and
approved by independent scientiﬁc committees with
experience in GPRD and MINAP studies.
The study population included patients aged
30 years and over who were hospitalised for troponin-
positive ACS in the period between 1 January 2002 and
30 September 2009. Patients who were discharged alive
from the hospital to home were followed from the date
of hospital discharge to death, transfer out of the gen-
eral practice, or the last data collection date. In case of
repeat ACS admissions in MINAP, one record was ran-
domly selected.
The characteristics of the ACS cases, as recorded in
MINAP and GPRD, were described. Mean and median
troponin levels were taken from the MINAP data,
whilst all other variables were taken from GPRD.
These included age, gender, alcohol use, socioeconomic
status, systolic blood pressure, and the ratio of total
cholesterol to high-density lipoprotein cholesterol. In
addition, smoking status and the extent of smoking
cessation interventions provided by the GP prior to
the ACS were described. Interventions were classiﬁed
into the following three groups:
a. prescribed pharmacological interventions for smok-
ing cessation;
b. GP smoking cessation advice or referral to
stop-smoking clinic (without pharmaceutical
interventions);
c. no GP intervention.
Counts and percentages and means and medians were
calculated as appropriate.
GPRD records of patients who smoked prior to their
ACS were searched for evidence of GP interventions for
smoking cessation in the 3 months following discharge.
This included events recorded using Read codes (the
coded thesaurus of clinical terms used by GPs in pri-
mary care), prescriptions and information recorded in
the free text. Evidence of quitting was also recorded.
Major clinical outcomes were explored in patients
who smoked prior to their ACS, stratiﬁed by quitting
status. The outcomes included death (as recorded in the
ONS mortality data), repeat ACS (as recorded in
MINAP or GPRD), stroke (as recorded in GPRD or
HES), heart failure (as recorded in GPRD or HES) and
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major adverse cardiac events (MACEs), deﬁned as
death, recurrent ACS, coronary artery bypass grafting
or target lesion revascularisation (deﬁned as percutan-
eous intervention or bypass surgery). GPRD and HES
were used to identify the cardiac procedures. Cox pro-
portional hazards regression was used to estimate the
absolute incidence and relative rates.
Results
Table 1 shows the characteristics of the 4834 patients
with ACS included in the study. Smoking status was
recorded for almost all patients, with approximately
20% classiﬁed as current smokers at the time of the
ACS event. Approximately 65% of patients were aged
70 or older at the time of the ACS and 61% were men.
However, amongst smokers, only 33% were aged 70 or
older and a higher proportion were men. The mean
systolic blood pressure, as recorded prior to the ACS
in GPRD, was elevated above normal, but not to the
level considered to be hypertensive. The median peak
troponin concentration during the hospitalisation, as
recorded in MINAP, was consistent with the diagnosis
of ACS.
Table 2 shows the concordance between smoking
status recorded prior to the admission by GPs (from
GPRD) and smoking status recorded on admission to
hospital for the ACS (from MINAP). Whilst smoking
status was more complete in the GPRD record, the
concordance between GPRD and MINAP data was
strong.
Tables 3 and 4 show the extent of GP smoking ces-
sation interventions amongst smokers prior to and after
the ACS hospitalisation, both overall (Table 3) and by
gender and age (Table 4). Prior to hospitalisation,
almost half of smokers had received no intervention,
and this proportion was higher amongst those aged at
least 80 years. In the 3 months following discharge,
over three-quarters received no intervention, despite
99% of patients having had some contact with their
GP. Again, the proportion of patients who received
Table 1. Characteristics of 4834 patients with acute coronary syndrome (ACS) by smoking status measured prior to hospitalisation.
Characteristics Non-smokers (1611) Ex-smokers (2122) Smokers (965) Unknown (136) Total (4834)
Men 743 (46.1%) 1437 (67.7%) 690 (71.5%) 81 (59.6%) 2951 (61.0%)
Age at ACS hospitalisation
30–39 6 (0.4%) 6 (0.3%) 23 (2.4%) 4 (2.9%) 39 (0.8%)
40–49 42 (2.6%) 41 (1.9%) 139 (14.4%) 9 (6.6%) 231 (4.8%)
50–59 149 (9.2%) 145 (6.8%) 248 (25.7%) 19 (14.0%) 561 (11.6%)
60–69 214 (13.3%) 395 (18.6%) 233 (24.1%) 20 (14.7%) 862 (17.8%)
70–79 468 (29.1%) 700 (33.0%) 204 (21.1%) 24 (17.6%) 1396 (28.9%)
80þ 732 (45.4%) 835 (39.3%) 118 (12.2%) 60 (44.1%) 1745 (36.1%)
Drinking status:
Non-drinker 310 (19.2%) 214 (10.1%) 109 (11.3%) 1 (0.7%) 634 (13.1%)
Ex-drinker 164 (10.2%) 244 (11.5%) 96 (9.9%) 1 (0.7%) 505 (10.4%)
Drinker 955 (59.3%) 1527 (72.0%) 657 (68.1%) 6 (4.4%) 3145 (65.1%)
Unknown 182 (11.3%) 137 (6.5%) 103 (10.7%) 128 (94.1%) 550 (11.4%)
Systolic BP: mean, median 139.1, 140.0 138.3, 139.0 137.8, 138.0 143.1, 140.0 138.6, 139.0
Total/HDL cholesterol:
7 971 (60.3%) 1530 (72.1%) 498 (51.6%) 19 (14.0%) 3018 (62.4%)
>7 29 (1.8%) 25 (1.2%) 39 (4.0%) 0 (0.0%) 93 (1.9%)
Unknown 611 (37.9%) 567 (26.7%) 428 (44.4%) 117 (86.0%) 1723 (35.6%)
Deprivation (IMD) quintile
0 (least deprived) 287 (17.8%) 328 (15.5%) 84 (8.7%) 17 (12.5%) 716 (14.8%)
1 378 (23.5%) 465 (21.9%) 158 (16.4%) 32 (23.5%) 1033 (21.4%)
2 351 (21.8%) 444 (20.9%) 203 (21.0%) 31 (22.8%) 1029 (21.3%)
3 317 (19.7%) 441 (20.8%) 237 (24.6%) 30 (22.1%) 1025 (21.2%)
4 (most deprived) 278 (17.3%) 444 (20.9%) 283 (29.3%) 26 (19.1%) 1031 (21.3%)
Peak troponin: mean, median 5.3, 0.8 6.8, 0.8 6.6, 0.8 5.0, 0.9 6.2, 0.8
BP: blood pressure; HDL: high-density lipoprotein; IMD: Index of Multiple Deprivation.
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no intervention in the 3 months following discharge
was higher amongst those aged at least 80 years.
Table 5 shows the change in smoking status and
number of cigarettes smoked per day from the last
GP record prior to hospitalisation to the ﬁrst GP
record in the three months after hospitalisation.
The number of cigarettes smoked per day was recorded
for 92% of smokers prior to hospitalisation. Of these,
approximately half (56%) had no change in smoking
status or number of cigarettes smoked per day, whilst
32% were recorded as ‘‘ex-smoker’’. A small propor-
tion had evidence of a decrease in the extent of smoking
recorded (9%) whilst a minority increased their con-
sumption (4%).
In total, 320 (33%) smokers quit within the ﬁrst 3
months following the ACS hospitalisation. Table 6
and Figure 1 show the incidence (per 1000 patient
years) and relative rate of major clinical outcomes in
ACS smokers by quitting status. The relative rate of
all-cause mortality, mortality due to neoplasms and
mortality due to diseases of the respiratory system
were signiﬁcantly lower in smokers who quit within 3
months of discharge compared with those who remained
smokers. There was also a signiﬁcantly lower rate of
MACE in smokers who quit. Other clinical outcomes,
including repeat ACS, stroke and heart failure, tended to
be lower in smokers who quit compared with those who
remained smokers but the diﬀerence was not signiﬁcant.
Table 4. Patterns of smoking cessation interventions in primary care by age and gender.
Pre-ACS intervention (ever) Post-ACS intervention (in 3 months following discharge)
Pharmacological Advice/referral None Pharmacological Advice/referral None
Men 175 (25.4) 192 (27.8) 323 (46.8) 102 (14.8) 69 (10.0) 519 (75.2)
Women 97 (35.3) 70 (25.5) 108 (39.3) 41 (14.9) 13 (4.7) 221 (80.4)
30–39 7 (30.4) 10 (43.5) 6 (26.1) 10 (43.5) 2 (8.7) 11 (47.8)
40–49 40 (28.8) 34 (24.5) 65 (46.8) 27 (19.4) 21 (15.1) 91 (65.5)
50–59 72 (29.0) 70 (28.2) 106 (42.7) 57 (23.0) 27 (10.9) 164 (66.1)
60–69 78 (33.5) 56 (24.0) 99 (42.5) 34 (14.6) 17 (7.3) 182 (78.1)
70–79 58 (28.4) 57 (27.9) 89 (43.6) 12 (5.9) 12 (5.9) 180 (88.2)
80þ 17 (14.4) 35 (29.7) 66 (55.9) 3 (2.5) 3 (2.5) 112 (94.9)
ACS: acute coronary syndrome.
Table 3. Patterns of smoking cessation interventions in primary care amongst 965 people who were
current smokers at the time of admission with acute coronary syndrome (ACS).
Coded data, n (%) Free text, n (%) Combined, n (%)
Intervention prior to ACS
Pharmacological 262 (27.1) 80 (8.3) 272 (28.2)
Advice/referral 7 (0.7) 374 (38.8) 262 (27.2)
None 696 (72.1) 511 (53.0) 431 (44.7)
3 months following ACS
Pharmacological 141 (14.6) 42 (4.4) 143 (14.8)
Advice/referral 4 (0.4) 107 (11.1) 82 (8.5)
None 820 (85.0) 816 (84.6) 740 (76.7)
Table 2. Concordance between primary care (General Practice
Research Database (GPRD)) and hospital registry (Myocardial
Ischaemia National Audit Project (MINAP)) records of smoking
status prior to admission.
Smoking status
recorded
in MINAP
Smoking status recorded in GPRD
Non-smoker Ex-smoker Smoker Unknown
Non-smoker 837 263 32 35
Ex-smoker 227 1311 123 46
Smoker 34 150 729 25
Unknown 513 398 81 30
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Discussion
This study of linked primary and secondary care data-
bases provides a unique longitudinal perspective on
smoking status and cessation interventions before and
after hospitalisation for ACS. The results show that a
minority of patients discharged from hospital after
ACS receive interventions for smoking and a large
number continue to smoke. This missed opportunity
for care is important because patients who continued
to smoke had a signiﬁcantly worse prognosis than those
who quit.
The use of linked GPRD and MINAP registry data
in this study provided a unique longitudinal perspective
on smoking patterns in patients before, during, and
after hospital admission with ACS. In the period
before presentation with ACS only 54% of smokers
received smoking cessation interventions, while in the
3 months after discharge, when motivation to stop was
likely much higher, only 23% of smokers received
smoking cessation interventions. The beneﬁts of smok-
ing cessation interventions are well established4–7 and
the demonstrated failure of adherence to guideline rec-
ommendations for smoking cessation interventions no
doubt contributed to the high proportion of smokers
who failed to quit after ACS and who were thereby
exposed to an increased risk of adverse outcomes.
The failure of adherence to guideline recommenda-
tions was particularly marked in older patients, consist-
ent with previous reports of systematic under-treatment
in this high-risk group.10–16 Whist some pharmaco-
logical interventions should be used with caution in
older people, it is widely accepted that there are no
circumstances in which it is safer to smoke than to
use nicotine replacement therapy.17 Smoking cessation
has been shown to increase the life expectancy of older
patients with cardiovascular disease, and is more eﬀect-
ive than most other interventions.18
This study has important limitations which are inher-
ent in any epidemiological study utilising databases.
Table 6. Incidence (per 1000 patient years) and relative rate of major clinical outcomes in smokers with acute coronary
syndrome (ACS) by quitting status.
Outcome
Smokers
n¼ 645 Incidence in smokers
Quitters
n¼ 320
Incidence in
quitters Relative rate
Mortality
All cause 149 105.1 (89.5–123.5) 43 50.2 (37.3–67.7) 0.49 (0.35–0.69)
Cancer 30 21.2 (14.8–30.3) 6 7.0 (3.2–15.6) 0.33 (0.14–0.80)
Cardiovascular 58 40.9 (31.6–52.9) 25 29.2 (19.7–43.2) 0.73 (0.46–1.17)
Respiratory 25 17.6 (11.9–26.11) 4 4.7 (1.8–12.5) 0.27 (0.09–0.78)
Repeat ACS 44 22.5 (16.7–30.2) 15 14.1 (8.5–23.4) 0.65 (0.36–1.17)
Stroke 19 15.1 (9.6–23.6) 7 8.9 (4.2–18.7) 0.59 (0.25–1.41)
Heart failure 28 22.8 (15.7 – 33.0) 15 19.2 (11.6–31.8) 0.86 (0.46–1.61)
MACE 185 167.8 (145.3–193.8) 69 98.0 (77.4–124.0) 0.61 (0.46–0.80)
MACE: major adverse cardiac event.
Table 5. Change in status and number of cigarettes smoked a day from last record pre-acute coronary syndrome (ACS) to first
record within 3 months of ACS.
Pre-ACS
Post-ACS (first record within 3 months of ACS)
Ex-smoker Up to 5 a day 6–10 a day 11–15 a day 16–20 a day Over 20 a day
Unknown
no.
Up to 5 a day 60 134 7 1 2 1 N/A
6–10 a day 76 22 126 5 7 0 N/A
11–15 a day 46 7 10 64 3 1 N/A
16–20 a day 76 9 9 7 112 5 N/A
Over 20 a day 22 4 4 3 5 55 N/A
Unknown no. 18 4 4 0 1 2 53
N/A: not applicable.
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Smoking status was derived from GP records, was not
validated, and may only have been recorded if the
patient visited the practice. Smoking cessation advice
may have been provided without being recorded in the
patient record; a recent pan-European cross-sectional
study found smoking cessation advice was not recorded
in a third of cases.19 GP recording of smoking sta-
tus and of advice against smoking may have changed
following the introduction in 2004 of the Quality and
Outcomes Framework contract which oﬀers ﬁnancial
incentives for the recording of smoking status
and advice.20,21 This is a descriptive observational
study and hence confounding may be present.
Patients were not randomised to GP interventions,
possibly leading to bias in the comparison of rates of
clinical outcomes.
As this study is descriptive and retrospective, its ﬁnd-
ings are not deﬁnitive. However, the results do support
future research, both in larger prospective epidemio-
logical studies and randomised controlled trials, of
the promotion of GP smoking cessation interventions,
the association between interventions and cessation and
the eﬀects on long-term clinical outcomes.
This descriptive study, utilising four linked datasets,
provides evidence that smoking is common amongst
those hospitalised for ACS. However, despite the
National Institute for Health and Clinical Excellence
guidelines, few GPs oﬀer smoking cessation advice,
referral to smoking clinics, or pharmacological inter-
vention in the 3 months following ACS discharge.
Given the lower rates of major clinical outcomes,
including mortality and MACE, amongst those who
quit smoking following ACS, there remains a signiﬁ-
cant opportunity for GPs to actively engage smokers
in cessation interventions.
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